Screener
Immunovant, Inc. IMVT Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Research and development | $456,660 | $360,917 | $212,928 |
| Acquired in-process research and development | — | — | 12,500 |
| General and administrative | 76,242 | 77,235 | 57,281 |
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s other operating expenses?
- Immunovant, Inc. (IMVT) reported other operating expenses of $159.55M in Q1 2026.
- How has Immunovant, Inc.'s other operating expenses changed year-over-year?
- Immunovant, Inc.'s other operating expenses increased by 40.2% year-over-year, from $113.83M to $159.55M.
- What is the long-term trend for Immunovant, Inc.'s other operating expenses?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s other operating expenses has grown at a 35.9% compound annual growth rate (CAGR), from $156.03M to $532.9M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Immunovant, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude